spacer
The Healthcare Sales & Marketing Network celebrates 28 years serving the medical sales & marketing community.Connecting Medical Sales Reps with MedTech/BioPharma Recruiters and Independent Reps with and New Product LinesConnecting Medical Sales Reps with MedTech/BioPharma Recruiters and Independent Reps with and New Product Lines

Searching News Database:  phospholipase A2 

 HSMN NewsFeed - 4 Dec 2025
SciNeuro Pharmaceuticals Announces $53 Million Financing to Further Advance Pipeline of Therapies for Neurodegenerative Diseases and Appointment of Chief Financial Officer
Biopharmaceuticals Neurology Venture Capital
 HSMN NewsFeed - 14 Nov 2016
Technopath Clinical Diagnostics Launches its First Diagnostic Reagent Product, the i-plaq(TM) Test for Lp-PLA2
Diagnostics Cardiology Product Launch
 HSMN NewsFeed - 7 Jul 2015
Diadexus, Inc. Names William Hammond as Vice President of Sales
Diagnostics Cardiology Personnel
 HSMN NewsFeed - 24 Oct 2013
Celsus Therapeutics Announces Appointment of Pablo Jimenez, M.D., to Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 29 Nov 2010
Amarin's AMR101 Meets Pivotal Phase 3 Study Endpoints With Highly Statistically Significant Reductions in Triglycerides at 4 Gram and 2 Gram Doses in MARINE Trial With No Statistically Significant Increase in LDL-C and Safety Profile Similar to Placebo
Biopharmaceuticals
 HSMN NewsFeed - 8 Feb 2010
Anthera Pharmaceuticals Announces Agreement With the FDA on a SPA for Planned Phase 3 Varespladib A-002 Study; Daniel K. Spiegelman Joins Board of Directors
Biopharmaceuticals Cardiology Personnel
 HSMN NewsFeed - 2 Sep 2008
Volcano's VH(R) IVUS Technology Used in Imaging Study of GlaxoSmithKline's Novel Investigational Compound, Darapladib
Devices Cardiology
 HSMN NewsFeed - 25 Aug 2008
Anthera Pharmaceuticals Advances Global Development Strategy for Varespladib in Patients With Acute Coronary Syndrome With the Initiation of FRANCIS Trial
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 13 Aug 2008
Anthera Pharmaceuticals Completes $19 Million Financing; Appoints Christopher S. Henney as Chairman
Biopharmaceuticals Personnel Venture Capital
 HSMN NewsFeed - 19 Feb 2008
diaDexus Receives FDA Clearance for Automated Blood Test That Identifies Stroke & Heart Attack Risk
DIagnostics Cardiology FDA
 HSMN NewsFeed - 8 Jan 2008
Anthera Pharmaceuticals Acquires the Worldwide Rights to a BAFF Inhibitor for the Treatment of Lupus and Other Autoimmune Diseases
Biopharmaceuticals Licensing
 HSMN NewsFeed - 18 Dec 2007
Anthera's A-001 Receives Orphan Drug Status for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
Biopharmaceuticals FDA
 HSMN NewsFeed - 5 Jul 2007
Study Shows Lp-PLA2 Identifies Individuals at Highest Risk for Ischemic Stroke
Diagnostics Neurology
 HSMN NewsFeed - 3 May 2007
diaDexus Appoints Charles Patrick to Board of Directors
Diagnostics Personnel
 HSMN NewsFeed - 1 May 2007
diaDexus Announces Two Key Executive Appointments
Diagnostics Personnel
 HSMN NewsFeed - 13 Apr 2007
First Patient Enrolled in Phase 2 'PLASMA' Trial With A-002 for Patients With Coronary Atherosclerosis
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 8 Mar 2007
Anthera Pharmaceuticals, Inc. Announces Formation of Clinical Advisory Board for Respiratory and Acute Care Programs
Biopharmaceuticals Personnel
 HSMN NewsFeed - 9 Jan 2007
Anthera Receives IND Approval from FDA to Begin Phase 2 'IMPACTS' Trial With A-001 for Prevention of Acute Chest Syndrome in Patients with Sickle Cell Disease
Biopharmaceuticals
 HSMN NewsFeed - 4 Jan 2007
Anthera Receives FDA Approval to Begin Phase 2 'PLASMA' Trial With A-002 for Patients With Coronary Atherosclerosis
Biopharmaceuticals Cardiology FDA
 HSMN NewsFeed - 7 Dec 2006
New Billing Code and Medicare Payment Recommendation Issued for Lp-PLA2 Testing
Diagnostics Cardiology Reimbursement
 HSMN NewsFeed - 14 Nov 2006
Studies Presented at AHA Confirm Role of Inflammatory Marker Lp-PLA2 in Assessing Cardiovascular Risk and in Secondary Prevention
Diagnostics Cardiology
 HSMN NewsFeed - 8 Nov 2006
diaDexus Reports Study Showing Lp-PLA2 Is an Independent Marker of Coronary Artery Disease and Death
Diagnostics Cardiology
 HSMN NewsFeed - 24 Oct 2006
Study Shows Inflammatory Enzyme Lp-PLA2 Predicts Recurrent Stroke
Diagnostics Cardiology Neurology
 HSMN NewsFeed - 13 Sep 2006
Anthera Pharmaceuticals Secures $36M Venture Financing to Initiate Clinical Programs
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 6 Sep 2006
Anthera Licenses Portfolio of Anti-Inflammatory Products From Eli Lilly and Company and Shionogi & Co., Ltd.
Biopharmaceuticals Licensing
 HSMN NewsFeed - 26 Jun 2006
New Data Published in an American Heart Association Journal Shows That Lipoprotein-Associated Phospholipase A2 Independently Adds to the Diagnostic Accuracy of Traditional Risk Assessment for Future Cardiovascular Events
Diagnostics Cardiology
Return to NewsFeed  

 Additional items found! 17

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 17 additional stories matching:
phospholipase A2
(Password required)
FindReps - screen and connect with rep candidates anonymously, in real time.

FindReps: Screen and connect with Medical Sales Rep candidates (Direct Reps and Independents) – anonymously, in real time.


RepJobs - Job Opportunities for Direct Sales Reps and New Product Lines for Independents!

RepJobs: Job Opportunities for Direct Sales Reps and New Product Lines for Independents!